Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MRSA - Methicillin-resistant Staphylococcus aureus -- Ignore unavailable to you. Want to Upgrade?

To: zen_lunatic420 who wrote (161)	5/1/2014 2:46:01 PM
From: CusterInvestor	Respond to of 191

AKAO new IPO has a drug in class III trials now. Their prospectus has some interesting info if you have some time. Our most advanced product candidate is plazomicin, a novel aminoglycoside designed by our scientists to overcome clinically relevant aminoglycoside resistance mechanisms. Aminoglycosides have been used successfully for the treatment of serious bacterial infections for more than 50 years. As a class, aminoglycosides have several important characteristics including rapid bactericidal activity, well-described PK, a lack of metabolism in humans, and excellent solubility and stability. However, the spread of resistance to currently marketed aminoglycosides has decreased their clinical utility. We developed plazomicin by chemically modifying an existing aminoglycoside, sisomicin, a natural product isolated from bacteria, to shield the regions of the molecule that are targeted by the enzymes responsible for aminoglycoside resistance. As a result of these modifications, plazomicin remains active against multi-drug resistant organisms where most other major drug classes, including commercially available aminoglycosides such as gentamicin and amikacin, have limited activity. Based on this profile, we are developing plazomicin as an intravenous, or IV, therapy for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE, which the CDC considers to be one of the top three urgent resistance threats to public health. A few tidbits that caught my eye: Under 12 million shares out and insiders own a lot. Fidelity just filed that they own 15%.

To: zen_lunatic420 who wrote (161)	5/1/2014 3:52:13 PM
From: Chris Forte	Respond to of 191

Great to hear from you, and thanks. Hope all is well. I'm not familiar with TSXV: COV, but thanks for pointing them out. I did a quick look at your very helpful link and I'm intrigued. If they can become the "gold standard" for certain wound care situations it certainly will be a big winner for you. Wound care is an important field. Sorry I can't offer more insight at this point. All I know is we should be assembling a core group of companies that will come into play once the general public becomes more aware of the looming danger of bacterial infections. I'm perplexed by our indifference to the problem. Eventually there will be a full court press for investment in this area. I fear we are taking this threat too lightly and eventually all our chickens will come home to roost because of our poor choices that created resistant superbugs.